WIRB-Copernicus Group Acquires Vigilare International

USA - English

• USA - Deutsch
• USA - Polski
• USA - Pусский
• USA - slovenčina
• USA - Français
• USA - čeština
• USA - español

PRINCETON, N.J., Nov. 28, 2017 /PRNewswire/ -- WIRB Copernicus Group® (WCG™), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced its acquisition of Vigilare International, the top provider of integrated, end-to-end pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry.

"We are delighted to welcome Vigilare to the WCG family of companies," said Donald A. Deieso, PhD, Chairman and CEO of WCG. "With its comprehensive service suite, Vigilare provides clients with streamlined, regulatory compliant operations, faster access to safety data and focused in-depth product safety reporting and analysis. Vigilare saves clients time and money by offering them a robust alternative to building and maintaining an internal pharmacovigilance and drug safety program."

"WCG is a perfect fit for Vigilare," said James A. Bannon, PharmD, President and CEO of Vigilare. "Our pharmacovigilance services are a natural complement to WCG's existing portfolio of clinical research optimization solutions. We look forward to working with our colleagues at WCG to identify additional opportunities to streamline clinical research operations, while improving the quality of product safety information."

Like the other members of the WCG family of companies, Vigilare will continue to operate as an independent service organization. WCG will support Vigilare as it continues to expand, with access to capital, complementary clinical and regulatory expertise, and corporate support.

Financial details about the transaction were not disclosed.

About WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry's first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protection. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.

About Vigilare International (Vigilare)
Vigilare offers product safety services in support of clinical trials and focused pharmacovigilance services in support of marketed products globally. Vigilare's experts are experienced healthcare practitioners working with every type of product, from drugs and devices to vaccines, to over-the-counter products and nutraceuticals.

SOURCE WIRB-Copernicus Group

Related Links

http://www.wcgclinical.com